Unlearn Partners with Trace Neuroscience to Advance Digital Twin Technology in Brain Health

**Unlearn Partners with Trace Neuroscience to Advance Digital Twin Technology in Brain Health**

*June 2024*

In a groundbreaking collaboration poised to redefine the landscape of neurological research and patient care, Unlearn, a leader in artificial intelligence-driven clinical trial optimization, has announced a strategic partnership with Trace Neuroscience, a cutting-edge neurotechnology company. The alliance aims to accelerate the development and application of digital twin technology in brain health, with the goal of improving diagnostics, monitoring, and treatment outcomes for neurological disorders.

### What Are Digital Twins in Healthcare?

Digital twins are virtual replicas of physical systems—in this case, human brains—that simulate biological processes in real time. In healthcare, digital twins can be used to model disease progression, predict treatment responses, and personalize medical interventions. By integrating patient-specific data, these models offer a dynamic and individualized representation of a person’s health status.

In the context of brain health, digital twins can be particularly transformative. Neurological conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and depression are complex and often progress unpredictably. Digital twin models can help researchers and clinicians better understand these diseases, identify biomarkers, and tailor therapies to individual patients.

### The Power of the Partnership

Unlearn has pioneered the use of digital twins in clinical trials through its proprietary TwinRCT™ platform, which generates synthetic control arms using historical patient data and machine learning. This approach reduces the need for placebo groups and accelerates the pace of clinical research.

Trace Neuroscience, on the other hand, brings deep expertise in neuroimaging, electrophysiology, and cognitive assessment. The company has developed advanced tools for capturing high-resolution brain activity data, which are essential for building accurate and responsive digital twin models.

By joining forces, Unlearn and Trace Neuroscience aim to create a new generation of digital twins that are not only more precise but also capable of real-time adaptation. These models will leverage Trace’s rich neurobiological datasets and Unlearn’s AI-driven simulation engines to map individual brain trajectories and predict disease outcomes with unprecedented accuracy.

### Key Objectives of the Collaboration

1. **Enhanced Clinical Trial Design**: The partnership will integrate Trace’s neurobiological data into Unlearn’s TwinRCT™ platform, enabling more robust and representative synthetic control groups for neurological trials. This could significantly reduce trial durations and improve statistical power.

2. **Personalized Brain Health Monitoring**: The digital twins developed through this collaboration will allow clinicians to monitor patients’ brain health over time, detect early signs of cognitive decline, and adjust treatments proactively.

3. **Accelerated Drug Development**: By simulating how patients with different neurological profiles respond to new therapies, the digital twins can help pharmaceutical companies identify promising drug candidates and optimize dosing strategies.

4. **Ethical and Inclusive Research**: The companies are committed to ensuring that their models are trained on diverse datasets to avoid biases and ensure equitable healthcare outcomes across populations.

### Expert Perspectives

Dr. Charles Fisher, CEO and founder of Unlearn, expressed enthusiasm about the partnership: “Our mission has always been to bring AI into the clinical trial process in a way that benefits patients. By collaborating with Trace Neuroscience, we’re taking a major step forward in applying digital twin technology to one of the most complex and critical areas of medicine—brain health.”

Dr. Maya Lin, Chief Scientific Officer at Trace Neuroscience, added: “Understanding the brain requires both high-fidelity data and sophisticated modeling. This partnership allows us to combine our strengths and create tools that could revolutionize how we diagnose and treat neurological diseases.”

### Looking Ahead

The Unlearn-Trace Neuroscience partnership marks a significant milestone in the evolution of digital health technologies. As the collaboration unfolds, the companies plan to publish joint research findings, engage with regulatory bodies, and expand their platform to include a broader range of neurological conditions.

With the global burden of neurological disorders rising and the demand for personalized medicine growing, the integration of digital twin technology into brain health offers a promising path forward. This partnership not only exemplifies the power of interdisciplinary collaboration but also signals a new era in how we understand and care for the human brain.

—

*For more information about Unlearn and Trace Neuroscience, visit their official websites or follow their updates on LinkedIn and Twitter.*